Diffusion Pharma rejects 'woefully inadequate' unsolicited offer; LifeSci launches proxy contest for board control

CervoMed Inc.

Director Eric Francois resigns effective Dec 16, 2022; Board reduces from 7 to 6 members.
Company reports active bidding stage in strategic review; encouraged by response from multiple parties.
Board rejects unsolicited offer from LifeSci client as woefully inadequate; encourages LifeSci to join process.
LifeSci commences proxy contest to replace board with its own nominees ahead of Dec 30, 2022 annual meeting.
Annual meeting of stockholders set for December 30, 2022, two weeks later than previously announced.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Eric Francois

director

CRVO · CervoMed Inc.

Effective: 2022-12-16
Filed: November 14, 2022, 6:59 PM ET

On November 13, 2022, Eric Francois resigned from the board of directors (the “Board”) of Diffusion Pharmaceuticals Inc. (the “Company”) and all committees and subcommittees thereof, effective as of December 16, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Eric Francois resigned as director at CervoMed Inc..

Action: resigned
Role: director

Exact text from the filing

On November 13, 2022, Eric Francois resigned from the board of directors (the “Board”) of Diffusion Pharmaceuticals Inc. (the “Company”) and all committees and subcommittees thereof, effective as of December 16, 2022.

View on SEC.gov

CervoMed Inc. filing history →

Source: SEC EDGAR

accession 0001437749-22-027044

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.